Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-07 · accession 0001415889-24-007569 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-11 | 2024-03-07 | KNSA | Patel Sanj K | COB, CEO, Dir | S - Sale | $21.02 | -65.0K | 0 | -100% | -$1.37M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Share | 2024-03-07 | S | D | 65,012 | $21.02 | 0 | I Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.00 and $21.145. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |